> For the complete documentation index, see [llms.txt](https://www.brexatlas.org/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.brexatlas.org/bre-001/bre-005.md). # BRE 005 ## Electric Fields and the Immune System **Clinical Cancer Names:** Lung Carcinoma, Colon Carcinoma, Hepatocellular Carcinoma, Ovarian Carcinoma **Common Cancer Names:** Lung Cancer, Colon Cancer, Liver Cancer, Ovarian Cancer ## Source Voloshin, T., Kaynan, N., Davidi, S., Porat, Y., Shteingauz, A., Schneiderman, R. S., Zeevi, E., Munster, M., Blat, R., Tempel Brami, C., Cahal, S., Itzhaki, A., Giladi, M., Kirson, E. D., Weinberg, U., Kinzel, A., & Palti, Y. (2020). *Tumor-Treating Fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy.* *Cancer Immunology and Immunotherapy, 69(7), 1191–1204.* *** ## BRE-005 Scoring Section **BRS Score**\ **BRS:** 8.6 / 10\ **STEMD:** S8 / T9 / E9 / M9 / D8\ **External Evidence Level:** Strong in-vitro and in-vivo immunotherapy-combination evidence ### Score Interpretation BRE-005 receives a strong score because it adds immune-system relevance to TTFields. Its key value is showing that TTFields may induce immunogenic cell death and enhance antitumor response when combined with anti-PD-1 therapy. ### Score Summary This study receives one of the highest scores in the encyclopedia because it expands TTFields beyond direct cancer-cell effects and into immune-system interactions. BRE-005 is important because it introduces a new possibility: Electric fields may not only attack cancer cells directly—they may also help the immune system recognize and attack cancer. *** ## Entry Summary The earlier BRE entries focused on three major ideas: * Cancer cells can respond to electric fields. * Frequency matters. * Electric fields may improve radiation response. BRE-005 introduces a fourth major idea: Electric fields may activate anti-cancer immunity. This study investigated whether TTFields could trigger a form of cell death that alerts the immune system and whether combining TTFields with anti-PD-1 immunotherapy could improve treatment response. BREXAtlas identifies this as one of the most important mechanism-expansion studies in the entire collection. *** ## Question This BRE Helps Answer
Can electric fields help the immune system fight cancer? What BREXAtlas found: Yes. The study found evidence that TTFields induced immunogenic cell death. Unlike ordinary cell death, immunogenic cell death sends signals that help the immune system recognize cancer as a threat. This distinction is important. A cancer cell can die quietly. Or it can die in a way that alerts the immune system. BRE-005 suggests TTFields may promote the second type.
Can electric fields improve immunotherapy? What BREXAtlas found: Yes. The study observed enhanced antitumor efficacy when TTFields were combined with anti-PD-1 therapy. Anti-PD-1 treatments work by helping immune cells recognize and attack cancer. TTFields appeared to increase that response. This raises an important possibility: Electric fields may function as immunotherapy amplifiers.
*** ## Cell Lines Cataloged in This Entry ### Lung Cancer * LLC-1 * H520 ### Colon Cancer * CT-26 ### Liver Cancer * HepG2 ### Ovarian Cancer * MOSE-L *** ## Treatment Parameters | Parameter | Value | | ----------------- | ---------------------------- | | Treatment Type | TTFields + Anti-PD-1 Therapy | | Frequency | 150–200 kHz | | Field Intensity | 175 V/m RMS | | Exposure Duration | 24–72 hours | ## Frequency Mapping | Cell Line | Cancer Type | Frequency | | --------- | -------------- | --------- | | LLC-1 | Lung Cancer | 150 kHz | | H520 | Lung Cancer | 150 kHz | | HepG2 | Liver Cancer | 150 kHz | | CT-26 | Colon Cancer | 200 kHz | | MOSE-L | Ovarian Cancer | 200 kHz | *** ## What BREXAtlas Found BRE-005 provides evidence that TTFields influence more than: * mitosis * frequency response * radiation sensitivity The study suggests TTFields also affect: * immune recognition * immune recruitment * immune activation This represents a major expansion of the BREXAtlas framework. *** ## Observed Responses Researchers reported: * Immunogenic cell death * Increased antitumor efficacy * Increased dendritic-cell maturation * Increased leukocyte recruitment * Increased IFN-γ production * Increased ATP release * Increased HMGB1 release * Increased calreticulin exposure * Enhanced anti-PD-1 response Taken together, these findings indicate stronger immune-system engagement. *** ## Why Does This Matter? Many cancer therapies attempt to kill cancer cells. This study suggests TTFields may also help expose cancer cells to the immune system. In simple language: Instead of only damaging cancer cells, TTFields may help the body notice those damaged cancer cells. That is a fundamentally different type of anti-cancer effect. *** ## Mechanisms ### MEC-011: Immunogenic Cell Death The central mechanism proposed in this study. Cancer cells die in a way that activates immune recognition. *** ### MEC-012: ATP Release ATP release functions as a distress signal that attracts immune activity. *** ### MEC-013: HMGB1 Release HMGB1 acts as a danger-associated molecular pattern that can stimulate immune responses. *** ### MEC-014: Calreticulin Exposure Calreticulin exposure helps immune cells identify damaged cells. *** ### MEC-015: Dendritic Cell Activation The study observed increased maturation of dendritic cells, which help initiate adaptive immune responses. *** ### MEC-016: Anti-PD-1 Amplification TTFields appeared to enhance anti-PD-1 immunotherapy effectiveness. *** ## Public Source Validation Public cancer-immunology literature recognizes immunogenic cell death as an important mechanism for activating anti-cancer immunity. This study is frequently cited because it connects TTFields with immunogenic cell death and immune-system activation. BREXAtlas interpretation remains consistent with the published findings while organizing them into the broader encyclopedia framework. *** ## Connections to Other BRE Entries ### Connected to BRE-001 BRE-001 established direct anti-cancer effects through mitotic disruption. BRE-005 expands TTFields into immune-system biology. Together they suggest TTFields may influence both cancer cells and the body's response to cancer. *** ### Connected to BRE-003 BRE-003 introduced the possibility that TTFields affect DNA repair. BRE-005 introduces immune activation. Together they suggest TTFields may influence multiple biological systems simultaneously. *** ### Connected to BRE-004 BRE-004 expanded TTFields beyond brain cancer. BRE-005 expands TTFields beyond direct cancer-cell biology. The two studies together support broader applicability across tissues and mechanisms. *** ### Connected to Future Immunotherapy Entries BRE-005 becomes the foundational immunotherapy entry of the encyclopedia. Future studies involving: * PD-1 * PD-L1 * checkpoint inhibition * immune activation * immune-cell recruitment should be compared directly against BRE-005. *** ## Research Gaps Identified ### RG-021: Immune Universality Gap Do all cancers demonstrate immunogenic cell death after TTFields exposure? ### RG-022: Combination Immunotherapy Gap Which immunotherapies benefit most from TTFields combination treatment? ### RG-023: Immune Biomarker Gap Can immune-response biomarkers predict TTFields success? ### RG-024: Long-Term Immune Memory Gap Can TTFields contribute to durable immune protection against recurrence? ### RG-025: Clinical Translation Gap Will immune-system effects observed in laboratory models translate into improved patient outcomes? *** ## Why This Entry Matters For researchers, BRE-005 is one of the strongest studies supporting immune-system involvement in bioelectric oncology. For patients and families, the message is simpler: TTFields may not only weaken cancer cells. They may also help the body's immune system recognize and attack those cancer cells. That possibility makes BRE-005 one of the most influential entries in the encyclopedia. *** ## Entry Conclusion BRE-005 marks the beginning of the immune-oncology branch of BREXAtlas. BRE-001 showed electric fields can disrupt cancer growth. BRE-002 showed frequency matters. BRE-003 showed radiation sensitivity may be affected. BRE-004 showed effects extend beyond brain cancer. BRE-005 reveals a new possibility: Electric fields may help the immune system join the fight against cancer. That discovery dramatically expands the scope of bioelectric oncology and opens an entirely new pathway for future research. --- # Agent Instructions This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com. ## Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter: ``` GET https://www.brexatlas.org/bre-001/bre-005.md?ask=&goal= ``` `ask` is the immediate question: it should be specific, self-contained, and written in natural language. `goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.